Santas, Enrique
Villar, Sandra
Palau, Patricia
Llàcer, Pau
de la Espriella, Rafael
Miñana, Gema
Lorenzo, Miguel
Núñez-Marín, Gonzalo
Górriz, Jose Luis
Carratalá, Arturo
Rodríguez, Enrique
Bayes-Genís, Antoni
Sanchis, Juan
Núñez, Julio
Funding for this research was provided by:
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (16/11/00420, 16/11/00403)
Article History
Received: 1 June 2024
Accepted: 4 September 2024
First Online: 17 September 2024
Competing interests
: J. Núñez received board speaker fees and travel expenses from Novartis, Roche Diagnostics, Abbott, Rovi, Vifor Pharma, Daiichi Sankyo, Boehringer Ingelheim, and Astra Zeneca (modest). J. Sanchis reveived speaker fees from Astra Zeneca, Abbott, and Edwards Lifesciences (modest). A. Bayés-Genís received board membership fees and travel expenses from Novartis, Roche Diagnostics, Vifor Pharma, and Critical Diagnostics (modest). JL Górriz, received consultancy fees from Astellas, GSK, CSL VIFOR, and speaker fees from AstraZeneca, Boehringer Ingelheim, Esteve, Bayer, Lilly, Astellas, and Novonordisk (modest). The remaining authors have no disclosures to report.